Noori, Soheila; Mirzababaei, Atieh; Amini, Mohammad Reza; Clark, Cain C. T.; Mirzaei, Khadijeh published the artcile< Effect of orlistat on serum uric acid level in adults: A systematic review and meta-analysis of randomised controlled trials>, Quality Control of 96829-58-2, the main research area is meta analysis orlistat uric acid reducing agent hyperuricemia.
Hyperuricemia increases the risk of gout and cardiovascular diseases. Obesity increases the risk of hyperuricemia while weight loss (>5 kg) has been reported to decrease urate. The effects of orlistat on serum uric acid (SUA) are still controversial. The aim of this meta-anal. was to evaluate the influence of orlistat on SUA levels in adults. Relevant studies, published up to May 2020, were searched systematically through PubMed/Medline, Scopus and Google Scholar. All relevant randomised controlled clin. trials were included. Meta-anal. was performed using random-effect model. Subgroup anal., sensitivity anal. and meta-regression were also carried out. Overall 7 trials (9 datasets) that enrolled 1786 subjects were included. Orlistat showed in a significant change in SUA level (Difference in means: -17.661μmol, 95% CI: -31.615 to -3.707, P = .01). A low heterogeneity observed across the studies (I2 = 25.119%). After categorising studies on the basis of duration and sample size, the effect of orlistat on SUA was significant. The results of meta-regression were showed that significant relationships were not found between orlistat and SUA in the duration of intervention. We found a significant reduction in SUA following orlistat therapy in adults.
International Journal of Clinical Practice published new progress about Adult, mammalian. 96829-58-2 belongs to class amides-buliding-blocks, and the molecular formula is C29H53NO5, Quality Control of 96829-58-2.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics